Last reviewed 2026-06-10 · How we verify

Unresectable urothelial carcinoma — Treatment Landscape & Competitive Intelligence

Unresectable urothelial carcinoma (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Unresectable urothelial carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Memorial Sloan Kettering Cancer Center · 1 drug in Unresectable urothelial carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Unresectable urothelial carcinoma:

• Unresectable urothelial carcinoma treatment updates — RSS
• Unresectable urothelial carcinoma treatment updates — Atom
• Unresectable urothelial carcinoma treatment updates — JSON

Cite this brief

Drug Landscape (2026). Unresectable urothelial carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unresectable-urothelial-carcinoma. Accessed 2026-06-10.

Related

• Unresectable urothelial carcinoma full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing